Astrazeneca Plc (AZN) 30.16 $AZN
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 30.16 (-0.04), LLY: 79.36 (-0.31), GSK: 43.75 (+0.03), BMY: 76.58 (+0.38)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 21.62 (-1.60), UTHR: 109.24 (-3.69), AZN: 30.16 (-0.04)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 241.17 (+1.47), VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), AMGN: 160.52 (-1.44)
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
PR Newswire - Fri Jul 01, 1:00AM CDT
Valeant Receives Upfront Payment & Milestone Payments from AstraZeneca In Exchange for Termination of European Rights to Brodalumab
VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), VRX.TO: 28.11 (-2.16)
AstraZeneca Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 23, 12:52PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 30.16 (-0.04)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.39% Gain
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 30.16 (-0.04)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), AZN: 30.16 (-0.04), GSK: 43.75 (+0.03)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 85.75 (-0.88), PFE: 36.31 (+0.07), MRK: 59.55 (-0.05), AZN: 30.16 (-0.04)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.34% Loss
Comtex SmarTrend(R) - Tue Jun 14, 1:47PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 30.16 (-0.04)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 1.34% Sell Off
Comtex SmarTrend(R) - Tue Jun 14, 1:45PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 30.16 (-0.04)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 30.16 (-0.04)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 30.16 (-0.04)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 241.17 (+1.47), IRWD: 12.34 (-0.42), AZN: 30.16 (-0.04), JNP: 7.51 (-0.12)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), VRX.TO: 28.11 (-2.16)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 30.16 (-0.04)
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
BusinessWire - Wed Jun 08, 7:00AM CDT
--21 abstracts on dapagliflozin, including an investigation of its effects on cardiovascular risk factors in type 2 diabetes with varying degrees of renal function and insights on its use in a real-world setting
AZN: 30.16 (-0.04)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 54.26 (-1.47), AZN: 30.16 (-0.04), RTRX: 18.09 (-0.48), BMY: 76.58 (+0.38)
Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
BusinessWire - Mon Jun 06, 11:38AM CDT
--Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
AZN: 30.16 (-0.04)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 54.26 (-1.47), AZN: 30.16 (-0.04), RTRX: 18.09 (-0.48), PBYI: 32.77 (-1.39)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 30.16 (-0.04), LLY: 79.36 (-0.31), GSK: 43.75 (+0.03), BMY: 76.58 (+0.38)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 21.62 (-1.60), UTHR: 109.24 (-3.69), AZN: 30.16 (-0.04)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 241.17 (+1.47), VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), AMGN: 160.52 (-1.44)
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
PR Newswire - Fri Jul 01, 1:00AM CDT
Valeant Receives Upfront Payment & Milestone Payments from AstraZeneca In Exchange for Termination of European Rights to Brodalumab
VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), VRX.TO: 28.11 (-2.16)
AstraZeneca Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 23, 12:52PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 30.16 (-0.04)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.39% Gain
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.80 to a high of $29.20. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.19 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 30.16 (-0.04)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), AZN: 30.16 (-0.04), GSK: 43.75 (+0.03)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 85.75 (-0.88), PFE: 36.31 (+0.07), MRK: 59.55 (-0.05), AZN: 30.16 (-0.04)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.34% Loss
Comtex SmarTrend(R) - Tue Jun 14, 1:47PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 30.16 (-0.04)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 1.34% Sell Off
Comtex SmarTrend(R) - Tue Jun 14, 1:45PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.32. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $27.56 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 30.16 (-0.04)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 30.16 (-0.04)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 30.16 (-0.04)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 241.17 (+1.47), IRWD: 12.34 (-0.42), AZN: 30.16 (-0.04), JNP: 7.51 (-0.12)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), VRX.TO: 28.11 (-2.16)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 30.16 (-0.04)
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
BusinessWire - Wed Jun 08, 7:00AM CDT
--21 abstracts on dapagliflozin, including an investigation of its effects on cardiovascular risk factors in type 2 diabetes with varying degrees of renal function and insights on its use in a real-world setting
AZN: 30.16 (-0.04)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 54.26 (-1.47), AZN: 30.16 (-0.04), RTRX: 18.09 (-0.48), BMY: 76.58 (+0.38)
Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
BusinessWire - Mon Jun 06, 11:38AM CDT
--Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
AZN: 30.16 (-0.04)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 54.26 (-1.47), AZN: 30.16 (-0.04), RTRX: 18.09 (-0.48), PBYI: 32.77 (-1.39)
